Botulinum toxin type A for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial

Mayo Clinic Proceedings

Volumn 80, Issue 9, 2005, Pages 1126-1137

  Silberstein, Stephen D ^a,f   Stark, Stuart R ^b   Lucas, Sylvia M ^c   Christie, Suzanne N ^d   DeGryse, Ronald E ^e   Turkel, Catherine C ^e  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Neurology and Headache Treatment Center   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^d Ottawa Headache Centre   (Canada)

^e ALLERGAN INC   (United States)

^f THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ADULT; AGED; ARTICLE; ASTHENIA; BACKACHE; CHRONIC DAILY HEADACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; FEMALE; HEADACHE; HUMAN; HYPESTHESIA; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; MUSCLE HYPERTONIA; MUSCLE RIGIDITY; MUSCLE WEAKNESS; NECK PAIN; PROPHYLAXIS; PTOSIS; RANDOMIZED CONTROLLED TRIAL; SHOULDER PAIN; SIDE EFFECT;

EID: 24144474227     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/80.9.1126     Document Type: Article

References (36)

1. Silberstein SD, Lipton RB. Chronic daily headache. Curr Opin Neurol. 2000;13:277-283.
2. Castillo J, Muñoz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache. 1999;39:190-196.
3. Welch KM, Goadsby PJ. Chronic daily headache: nosology and pathophysiology. Curr Opin Neurol. 2002;15:287-295.
4. Pascual J, Colas R, Castillo J. Epidemiology of chronic daily headache. Curr Pain Headache Rep. 2001;5:529-536.
5. Wang SJ, Fuh JL, Lu SR, et al. Chronic daily headache in Chinese elderly, prevalence, risk factors, and biannual follow-up. Neurology. 2000; 54:314-319.
6. Scher AI, Lipton RB, Stewart W. Risk factors for chronic daily headache. Curr Pain Headache Rep. 2002;6:486-491.
7. Newman LC, Lipton RB, Solomon S, Stewart WF. Daily headaches in a population sample: results from the American Migraine Study [abstract]. Headache. 1994;34:295. Abstract 6.
8. Mathew NT. Chronic refractory headache. Neurology. 1993;43(6, suppl 3):S26-S33.
9. Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC. Features of medication overuse headache following overuse of different acute headache drugs. Neurology. 2002;59:1011-1014.
10. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology. 1996;47:871-875.
11. Mathew NT, Reuveni U, Perez F. Transformed or evolutive migraine. Headache. 1987;27:102-106.
12. Bigal ME, Sheftell FD, Rapoport AM, Tepper SJ, Lipton RB. Chronic daily headache: identification of factors associated with induction and transformation. Headache. 2004;42:575-581.
13. Welch KMA, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache. 2001;41:629-637.
14. Silberstein SD, US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [published correction appears in Neurology. 2000;56:142]. Neurology. 2000; 55:754-762.
15. Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache. 2003;43:171-178.
16. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia. 2003;23:820-824.
17. Saper JR, Lake AE III, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002;42:470-482.
18. Spira PJ, Beran RG, Australian Gabapentin Chronic Daily Headache Group. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology. 2003;61:1753-1759.
19. Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia. 2002;22:491-512.
20. Redillas C, Solomon S. Prophylactic pharmacological treatment of chronic daily headache. Headache. 2000;40:83-102.
21. Brandes JL, Saper JR, Diamond M, et al, MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291:965-973.
22. Silberstein SD, Neto W, Schmitt J, Jacobs D, MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61:490-495.
23. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache. 2003;43(suppl 1):S16-S24.
24. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003;43(suppl 1):S9-S15.
25. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125-133.
26. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44:35-42.
27. Silberstein S, Mathew N, Saper J, Jenkins S, BOTOX® Migraine Clinical Research Group. Botulinum toxin type A as a migraine preventive treatment. Headache. 2000;40:445-450.
28. Barrientos N, Ghana P. Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. J Headache Pain. 2003;4:146-151.
29. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C, BOTOX CDH Study Group. Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45:293-307.
30. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
31. Blumenfeld AM, Binder W, Silberstein SD, Blitzer A. Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache. 2003;43:884-891.
32. Siegel S. Nonparametric Statistics for the Behavioral Sciences. New York, NY: McGraw-Hill; 1956:116-127.
33. Sanin LC, Mathew NT, Bellmeyer LR, Ali S. The International Headache Society (IHS) headache classification as applied to a headache clinic population. Cephalalgia. 1994;14:443-446.
34. Couch JR Jr. Placebo effect and clinical trials in migraine therapy. Neuroepidemiology. 1987;6:178-185.
35. Linde M, May A, Limmroth V, Dahlof C, Headache Masters Programme. Ethical aspects of placebo in migraine research. Cephalalgia. 2003;23:491-495.
36. Blumenfeld A. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Headache. 2003;43:853-860.